| Synonyms |
Ranitidine Bismutrex|UNII-7AJ51I17KG|7AJ51I17KG|GR 122311X|Ranitidine (bismuth citrate)|Azamplus|Elicodil|Helirad|Pylorisan|Ranitidine bismuth citrate [USAN:BAN]|SCHEMBL415304|CHEMBL2111286|N-(2-((5-((Dimethylamino)methyl)furfuryl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine, compound with bismuth(3(+)) citrate (1:1)|1,2,3-Propanetricarboxylic acid, 2-hydroxy-, bismuth(3(+)) salt (1:1), compd. with N-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine (1:1)|1,2,3-Propanetricarboxylic acid, 2-hydroxy-, bismuth(3+) salt (1:1), compd. with N-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine (1:1)|N-(2-((5-((Dimethylamino)methyl)furfuryl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine, compound with bismuth(3+) citrate (1:1) |
| IUPAC Name |
bismuth;1-N'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine;2-hydroxypropane-1,2,3-tricarboxylate |
| Molecular Weight |
712.486 |
| Molecular Formula |
C13H22N4O3S?C6H5BiO7 |
| Canonical SMILES |
CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C.C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Bi+3] |
| InChI |
InChI=1S/C13H22N4O3S.C6H8O7.Bi/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3;7-3(8)1-6(13,5(11)12)2-4(9)10;/h4-5,9,14-15H,6-8,10H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);/q;;+3/p-3 |
| InChIKey |
XAUTYMZTJWXZHZ-UHFFFAOYSA-K |
| Boiling Point |
437.1°C at 760mmHg |
| Flash Point |
218.2°C |
| Purity |
95% |
| Density |
1.184g/cm3 |
| Solubility |
In vitro:
10 mM in DMSO |
| Appearance |
Solid powder |
| Storage |
Store at -20°C |
| Complexity |
558 |
| Exact Mass |
712.12519 |
| In Vitro |
Ranitidine bismuth citrate (0.1-1 μM, 5 min) is a potent irreversible inhibitor of both the ATPase (IC50=0.69 µM, Ki =0.97 µM ) and DNA-unwinding (IC50 =0.74 µM, Ki =0.39 µM) of the SARS-CoV-2 helicase. Ranitidine bismuth citrate (24 hours) shows potent activity against SARS-CoV-2 with an EC50 value of 2.3 μM in Vero E6 cells. |
| In Vivo |
Ranitidine bismuth citrate (150 mg/kg; intranasally inoculation; once daily; 4 days) suppresses SARS-CoV-2 replication, and relieves virus-associated pneumonia in a golden Syrian hamster model. Ranitidine bismuth citrate (48 mg/kg, i.p.) is effective in eradicating H. pylori and H. mustelae in female ferrests with MIC values of 8 ng/L and 1-2 ng/L, respectively. Ranitidine bismuth citrate (0.1 mg/kg, 0.3 mg/kg; p.o.) is effective in inhibiting gastric acid secretion and (1.0 mM) inhibits human pepsin isoenzymes activity. Animal Model: Male and female Syrian hamsters (6-10 weeks) Dosage: 150 mg/kg Administration: Intranasally inoculation; intraperitoneally given; once daily; 4 days Result: Suppressed SARS-CoV-2 replication, and relieved virus-associated pneumonia in a golden Syrian hamster model. Animal Model: Female Beagle dogs (14-20 kg) Dosage: 0.1 mg/kg Administration: Oral dosed every hour, for 5 hours Result: Inhibited gastric acid secretion. Animal Model: Female, random-bred hooded rats (weight range 90-120 g) Dosage: 0.5 mL/100 g Administration: Pre-treated with indomethacin (5 mg/kg s.c.); oral gavage Result: Inhibited gastric mucosal damage in the rat. |
| PSA |
252.18000 |
| Target |
IC50: 3.3 μM |
| Vapor Pressure |
7.66E-08mmHg at 25°C |
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/128345-62-0.gif)
